CD40LG and myocardial infarction: In this dose-escalation Rituximab in patients with acute ST-elevation myocardial infarction (RITA-MI) phase 1/2a study, a single rituximab infusion (200–1000 mg) administered in the acute ST-elevation MI (STEMI) setting was safe, induced rapid (~ 96%) depletion of circulating CD19+ B cells within minutes, and did not lower total IgG/IgM/IgA levels over 6 months, while repopulation was dose-dependent [114].